JPMorgan Chase & Co. Lowers Omnicell (NASDAQ:OMCL) Price Target to $57.00

Omnicell (NASDAQ:OMCLGet Rating) had its price target dropped by equities research analysts at JPMorgan Chase & Co. from $140.00 to $57.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 8.28% from the company’s previous close.

A number of other equities analysts also recently commented on the company. StockNews.com initiated coverage on Omnicell in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Wells Fargo & Company reduced their price target on shares of Omnicell from $158.00 to $71.00 and set an “overweight” rating on the stock in a research report on Friday, November 4th. Benchmark lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Thursday, November 3rd. Bank of America assumed coverage on shares of Omnicell in a research report on Friday, September 9th. They set a “buy” rating and a $120.00 price target for the company. Finally, Piper Sandler cut their price objective on Omnicell from $145.00 to $58.00 in a research report on Wednesday, November 2nd. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $82.44.

Omnicell Trading Down 0.9 %

OMCL stock opened at $52.64 on Friday. The company has a quick ratio of 1.86, a current ratio of 2.25 and a debt-to-equity ratio of 0.50. The company has a market cap of $2.33 billion, a price-to-earnings ratio of 51.61, a PEG ratio of 1.73 and a beta of 1.01. The business has a fifty day simple moving average of $75.51 and a 200-day simple moving average of $98.33. Omnicell has a 52 week low of $46.19 and a 52 week high of $187.29.

Insider Buying and Selling

In other Omnicell news, CFO Peter J. Kuipers sold 15,500 shares of the firm’s stock in a transaction that occurred on Friday, August 26th. The stock was sold at an average price of $108.29, for a total transaction of $1,678,495.00. Following the completion of the sale, the chief financial officer now owns 61,326 shares in the company, valued at approximately $6,640,992.54. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Omnicell news, CFO Peter J. Kuipers sold 11,000 shares of the firm’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $105.93, for a total transaction of $1,165,230.00. Following the completion of the transaction, the chief financial officer now directly owns 61,326 shares of the company’s stock, valued at approximately $6,496,263.18. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Peter J. Kuipers sold 15,500 shares of the business’s stock in a transaction dated Friday, August 26th. The stock was sold at an average price of $108.29, for a total transaction of $1,678,495.00. Following the completion of the sale, the chief financial officer now directly owns 61,326 shares of the company’s stock, valued at approximately $6,640,992.54. The disclosure for this sale can be found here. Insiders own 2.76% of the company’s stock.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently bought and sold shares of the company. Mutual of America Capital Management LLC lifted its holdings in Omnicell by 20.5% during the 1st quarter. Mutual of America Capital Management LLC now owns 53,240 shares of the company’s stock worth $6,894,000 after buying an additional 9,045 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in Omnicell by 40.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 95,583 shares of the company’s stock worth $12,377,000 after purchasing an additional 27,750 shares during the period. Steward Financial Group LLC increased its stake in Omnicell by 56.0% during the first quarter. Steward Financial Group LLC now owns 9,017 shares of the company’s stock valued at $1,158,000 after purchasing an additional 3,238 shares during the last quarter. Torray LLC raised its holdings in shares of Omnicell by 5.0% during the first quarter. Torray LLC now owns 9,411 shares of the company’s stock worth $1,219,000 after purchasing an additional 450 shares during the period. Finally, Avory & Company LLC lifted its position in shares of Omnicell by 46.0% in the 1st quarter. Avory & Company LLC now owns 67,108 shares of the company’s stock worth $8,690,000 after buying an additional 21,139 shares during the last quarter.

Omnicell Company Profile

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

See Also

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.